IL-10 and IFN-γ in Guillain-Barre syndrome

被引:32
作者
Press, R [1 ]
Deretzi, G
Zou, LP
Zhu, J
Fredman, P
Lycke, J
Link, H
机构
[1] Karolinska Inst, Huddinge Univ Hosp, Dept Neurol, Neuroimmunol Unit, SE-14186 Huddinge, Sweden
[2] Cent Hosp Molndal, Neurochem Lab, Molndal, Sweden
[3] Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden
关键词
Guillain-Barre syndrome; IL-10; IFN-gamma; cytokines; anti-ganglioside antibodies; ELISPOT;
D O I
10.1016/S0165-5728(00)00388-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Guillain-Barre syndrome (GBS) is an acute inflammatory disease affecting myelin and axons of the peripheral nervous system (PNS). GBS is considered to be caused by breakdown of tolerance to autoantigens of the PNS. The involvement of cytokines in GBS and in relation to treatment with high dose intravenous immunoglobulin (IvIg) is incompletely known. We studied the temporal profiles of IL-10 and IFN-gamma -secreting blood mononuclear cells (MNC) over the course of GBS, using enzyme-linked immunospot (ELISPOT) assays. Pretreatment levels of blood MNC spontaneously secreting IL-10 were higher in the acute phase of GBS than in control patients with aseptic meningitis, other neurological diseases, diabetic neuropathy and healthy subjects. Levels of IFN-gamma -secreting blood MNC were not increased over the course of GBS. Patients treated with IvIg had lower numbers of IL-10-secreting MNC compared to untreated patients. High levels of IL-10-secreting MNC correlated with serum anti-ganglioside IgM antibody levels, and with neurophysiological signs of axonal damage. The present data suggests that IFN-gamma is not involved in GBS pathogenesis, and IL-10 being up-regulated in the early phase of GBS and associated with axonal damage, may have a pathogenetic role in GBS. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:129 / 138
页数:10
相关论文
共 28 条
[1]
Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes macrophages [J].
Andersson, J ;
SkansenSaphir, U ;
Sparrelid, E ;
Andersson, U .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 :10-20
[2]
Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies [J].
Ang, CW ;
Yuki, N ;
Jacobs, BC ;
Koga, M ;
Van Doorn, PA ;
Schmitz, PIM ;
Van der Meché, FGA .
NEUROLOGY, 1999, 53 (09) :2122-2127
[3]
[Anonymous], 1978, Ann Neurol, V3, P565
[4]
AUKRUST P, 1994, BLOOD, V84, P2136
[5]
CLINICAL CORRELATION WITH SERUM-SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN GUILLAIN-BARRE-SYNDROME [J].
BANSIL, S ;
MITHEN, FA ;
COOK, SD ;
SHEFFET, A ;
ROHOWSKYKOCHAN, C .
NEUROLOGY, 1991, 41 (08) :1302-1305
[6]
IgM anti-GM1 antibodies in the Guillain-Barre syndrome: A serological predictor of the clinical course [J].
Bech, E ;
Orntoft, TF ;
Andersen, LP ;
Skinhoj, P ;
Jakobsen, J .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (01) :59-66
[7]
Clinical presentation and outcome of Guillain-Barre and related syndromes in relation to anti-ganglioside antibodies [J].
Carpo, M ;
Pedotti, R ;
Allaria, S ;
Lolli, F ;
Matà, S ;
Cavaletti, G ;
Protti, A ;
Pomati, S ;
Scarlato, G ;
Nobile-Orazio, E .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 168 (02) :78-84
[8]
CHALON MP, 1993, ACTA NEUROL SCAND, V87, P77
[9]
Circulating transforming growth factor beta 1 (TGF-β1) in Guillain-Barre syndrome:: decreased concentrations in the early course and increase with motor function [J].
Créange, A ;
Bélec, L ;
Clair, B ;
Degos, JD ;
Raphaël, JC ;
Gherardi, RK .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (02) :162-165
[10]
T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barre syndrome [J].
Dahle, C ;
Ekerfelt, C ;
Vrethem, M ;
Samuelsson, M ;
Ernerudh, J .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 153 (01) :54-60